Skip to content

Retsevmo 40 mg hard capsules

DRUG4 trials

Sponsors

Oslo University Hospital HF, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Rigshospitalet, Universita' Degli Studi Di Torino

Conditions

Advanced solid tumorCancerMultiple myelomaNon Small Cell Lung CancerNon-Hodgkin lymphomaT-cell prolymphocytic leukemia

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1
Start: 2016-07-25Target: 3000Updated: 2025-12-19
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling
RecruitingCTIS2023-510527-29-00
RigshospitaletCancer
Start: 2020-09-01Target: 600Updated: 2025-04-25
Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Oslo University Hospital HFCancer
Start: 2021-04-01Target: 6000Updated: 2026-01-22
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
Not yet recruitingCTIS2026-525268-16-00
Universita' Degli Studi Di TorinoNon Small Cell Lung Cancer
Target: 962Updated: 2026-10-19

Related Papers